Latest News for: dll3

Edit

Next-generation anti-DLL3 radiopharmaceuticals targeting high-grade neuroendocrine lung and prostate cancers

PNAS 02 Feb 2026
.
Edit

Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in ...

Nasdaq Globe Newswire 02 Feb 2026
MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics ...
Edit

Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026 (Form 6-K) (Molecular Partners AG)

Public Technologies 02 Feb 2026
"I am highly encouraged by the data generated in my group suggesting a favorable distribution profile of MP0712, a DLL3-targeted radiopharmaceutical for patients with SCLC and NEC cancers," said Dr.
Edit

TellDx-Enabled Circulating Tumor Cell Analysis Predicts Response to DLL3-Targeted Therapy in Small Cell Lung Cancer

Nasdaq Globe Newswire 14 Jan 2026
-- Study Results Support the use of TellDx to Personalize Cancer Care Management – ... .
Edit

DLL3-Targeted Immunotherapy Competitor Analysis Report 2025: The Field Still is in Mid-stage Clinical Development Without ...

Nasdaq Globe Newswire 27 Nov 2025
DLL3-targeted immunotherapies present promising opportunities in treating small cell lung cancer (SCLC) and neuroendocrine carcinomas (NECs) due ...
  • 1

Article Search

tools
×
×
×
×